Key result
STEMI incidence declines ~83% over 35 years in Iceland alongside falling NSTEMI rates.
Why the study?
STEMI incidence has declined while NSTEMI incidence has plateaued or increased, but the reasons for these changing temporal trends have yet to be explained.
Cohort (n=10,348)
Yes
A nationwide 35-year cohort study in Iceland demonstrated a significant long-term decline in the incidence of both STEMI and NSTEMI, suggesting that population-level risk factor changes and cardioprotective therapies have influenced atherosclerotic plaque burden beyond just the uptake of highly sensitive biomarkers.
Answers are grounded in this paper and cite their sources.
Declining first MI incidence supports sustained risk factor modification; leaves open generalizability to other populations and eras.
OBJECTIVES: Temporal trends in the incidence of ST-elevation myocardial infarction (STEMI) have been declining in many countries, while the incidence of non-ST elevation myocardial infarction (NSTEMI) has reached a plateau or even increased. The reasons for these changing trends have yet to be explained. We analysed these trends and short-term mortality from acute coronary syndromes in a nationwide cohort study over 35 years in Iceland. DESIGN: Retrospective cohort study using a national MI registry. SETTING: Iceland. PARTICIPANTS: All cases of myocardial infarction in individuals aged 25-74 years in Iceland 1981-2015. METHODS: Each case was classified as STEMI, NSTEMI or no ECG taken. ECG recordings were classified according to Minnesota criteria. OUTCOME MEASURES: Trends of STEMI and NSTEMI incidence and 1-day and 28-day mortality were obtained from the National Death Registry. RESULTS: A total of 10 348 cases were identified (mean age 61 years, 76.4% male). These were categorised as STEMI (32.7%), NSTEMI (45.8%) and no ECG taken (21.5%). We detected a significant 3.7% annual decline in the incidence of first MI. The age-adjusted incidence of STEMI showed an 83.2% decline, most pronounced after 1994, while for NSTEMI the decline was 66.5%, reaching a plateau from the year 1989 onwards. In Iceland, the uptake of highly sensitive biomarkers was initiated in 1997 (cardiac troponin T) and 2012 (high-sensitive troponin T), respectively. CONCLUSIONS: The different temporal trends in the incidence of STEMI and NSTEMI cannot be explained only by the uptake of highly sensitive biomarkers in 1997 and 2012. The change in population-level risk factor exposure is likely to have influenced atherosclerotic plaque burden and thrombotic mechanisms. Finally, increasing uptake of cardioprotective pharmacological and interventional therapy may have resulted in a primary preventive effect on plaque rupture and thrombosis and thus on the rates of STEMI and NSTEMI disproportionally.
No takes yet. Share an insight, caveat, or question.
Bjarnadóttir et al. (2025) conducted a cohort in Myocardial infarction (STEMI and NSTEMI) (n=10,348). Temporal trends was evaluated on Trends of STEMI and NSTEMI incidence and 1-day and 28-day mortality. Over 35 years in Iceland, the age-adjusted incidence of STEMI declined by 83.2%, while NSTEMI declined by 66.5% and plateaued after 1989, with an overall 3.7% annual decline in first MI incidence.
Synapse has enriched 10 related papers. Consider them for comparative context: